AD1801 – Alzheimer’s disease

AD1801 is an innovative project to develop disease modifying treatment of Alzheimer’s disease, targeting a different molecule than those targeted in the projects BAN2401 and BAN2401 back-up.

In August 2018, BioArctic obtained exclusive rights to develop antibody treatments for Alzheimer’s disease from a research project jointly owned with Eisai. The partner Eisai has the rights to develop small molecule treatment from this research project with a different target than those in the projects BAN2401 and BAN2401 back-up.